Racial differences in depressive symptoms and self-rated health among breast cancer survivors on aromatase inhibitor therapy

Journal of Psychosocial Oncology

Volumn 33, Issue 3, 2015, Pages 263-277

  Calhoun, Carla ^a   Helzlsouer, Kathy J ^a,b   Gallicchio, Lisa ^a,b,c  

^a MERCY MEDICAL CENTER   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

aromatase inhibitors; breast cancer; depression; endocrine therapy; estrogen; estrogen receptor positive; self rated health

Indexed keywords

AROMATASE INHIBITOR;

ADULT; AGED; ARTICLE; BLACK PERSON; BREAST CANCER; CANCER PAIN; CANCER SURVIVOR; CAUCASIAN; CONTROLLED STUDY; DEPRESSION; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MENTAL HEALTH; QUESTIONNAIRE; RACE DIFFERENCE; AFRICAN AMERICAN; BREAST NEOPLASMS; CHEMICALLY INDUCED; ETHNOLOGY; HEALTH DISPARITY; MIDDLE AGED; PSYCHOLOGY; RISK ASSESSMENT; SELF EVALUATION; STATISTICS AND NUMERICAL DATA; SURVIVOR;

AFRICAN AMERICANS; AGED; AROMATASE INHIBITORS; BREAST NEOPLASMS; DEPRESSION; DIAGNOSTIC SELF EVALUATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH STATUS DISPARITIES; HUMANS; MIDDLE AGED; RISK ASSESSMENT; SURVIVORS;

EID: 84929666795     PISSN: 07347332     EISSN: 15407586     Source Type: Journal    
DOI: 10.1080/07347332.2015.1019661     Document Type: Article

References (45)

1. Bailis, D. S., Segall, A., & Chipperfield, J. G. (2003). Two views of self-rated general health status. Social Science & Medicine, 56, 203-217.
2. Baum, M. (2001). The ATAC (arimidex, tamoxifen, alone or in combination) adjuvant breast cancer trial in post-menopausal (PM) women. San Antonio Breast Cancer Symposium.
3. Baum, M., Budzar, A. U., Cuzick, J., Forbes, J., Houghton, J. H., Klijn, J. G., et al. (2002). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet, 359(9324), 2131-2139.
4. Benyamini, Y., Leventhal, E. A., & Leventhal, H. (2003). Elderly people's ratings of the importance of health-related factors to their self-assessments of health. Social Science & Medicine, 56, 1661-1667.
5. Black, P. (1979). Management of cancer pain: An overview. Neurosurgery, 5(4), 507-512.
6. Bower, J. E. (2008). Behavioral symptoms in breast cancer patients and survivors: Fatigue, insomnia, depression, and cognitive disturbance. Journal of Clinical Oncology, 26(5), 768-777.
7. Burgess, C., Cornelius, V., Love, S., Graham, J., Richards, M., & Ramirez, A. (2005). Depression and anxiety in women with early breast cancer: Five year observational cohort study. British Medical Journal, 330, 702.
8. Campbell, C., & Edwards, R. (2008). Mind-body interactions in pain: The neurophysiology of anxious and catastrophic pain-related thoughts. Translational Research, 153(3), 97-101.
9. Cella, D., & Fallowfield, L. (2007). Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Research and Treatment, 107, 167-180.
10. Conte, P., & Frassoldati, A. (2007). Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective. The Breast Journal, 13(1), 28-35.
11. Ell, K., Sanchez, K., Vourlekis, B., Lee, P., Dwight-Johnson, M., Lagomasino, I., ⋯ Russell, C. (2005). Depression correlates of depression, and receipt of depression care among low-income women with breast or gynecologic cancer. Journal of Clinical Oncology, 23(13), 3052-3060.
12. Eversley, R., Dstrin, D., Dibble, S., Wardlaw, L., Pedrosa, M., & Favila-Penne, W(2005). Post-treatment symptoms among ethnic minority breast cancer survivors. Oncology Nursing Forum, 32, 250-256.
13. Fann, J. R., Thomas-Rich, A. M., Katon, W. J., Cowley, D., Pepping, M., McGregor, B. A., & Grawlo, J. (2008). General Hospital Psychiatry, 30, 112-126.
14. Fontaine, C., Meulemans, A., Huizing, M., Collen, C., Kaufman, L., De Mey, J., ⋯ De Greve, J. (2008). Tolerance of adjuvant letrozole outside of clinical trials. The Breast, 17, 376-381.
15. Gallicchio, L., MacDonald, R., Wood, B., Rushovich, E., & Helzlsouer, K. J. (2012). Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapy. Climateric, 15, 339-359.
16. Gallicchio, L., Calhoun, C., & Helzlsouer, K. J. (2013). Association between race and physical functioning limitations among breast cancer survivors. Supportive Care in Cancer, doi10.1007/s00520-013-2066-2
17. Gupta, P., Sturdee, D. W., Palin, S. L., Majumder, K., Fear, R., Marshall, T., & Paterson, I. (2006). Menopausal symptoms in women treated for breast cancer: The prevalence and severity of symptoms and their perceived effects on quality of life. Climacteric, 9, 49-58.
18. Halbreich, U. (1997). Role of estrogen in postmenopausal depression. Neurology, 48, 16S-20S.
19. Hayes, D. F. (2007). Follow-up of patients with early breast cancer. The New England Journal of Medicine, 356, 2505-2513.
20. Helzlsouer, K. J., Gallicchio, L., MacDonald, R., Wood, B., & Rushovich, E. (2011). A prospective study of aromatase inhibitor therapy, vitamin D, c-reactive protein and musculoskeletal symptoms. Breast Cancer Research and Treatment, doi:10.1007/s10549-011-1729-2
21. Idler, E. L., & Benyamini, Y. (1997). Self-rated health and mortality: A review of twenty-seven community studies. Journal of Health and Social Behavior, 38, 21-37.
22. Irwin, M. R., Olmstead, R. E., Ganz, P. A., & Haque, R. (2013). Sleep disturbance, inflammation and depression risk in cancer survivors. Brain, Behavior, and Immunity, 30(Suppl) S58-S67.
23. Jones, S. E., Cantrell, J., Vukelja, S., Pippen, J., O'Shaughnessy, J., Blum, J., ⋯ Asmar, L. (2007). Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: Report of a tamoxifen exemestand adjuvant multicenter trial substudy. Journal of Clinical Oncology, 25(30), 4765-4771.
24. Jylha, M. (2009). What is self-rated health and why does it predict mortality? Towards a unified conceptual model. Social Science & Medicine, 69, 307-316.
25. Katz, J., Poleshuck, E., Andrus, E., Hogan, L., Jung, B., Kulick, D., & Dworkin, R. (2005). Risk factors for acute pain and its persistence following breast cancer surgery. Pain, 119, 16-25.
26. Kemp, A., Preen, D. B., Saunders, C., Boyle, F., Bulsara, M., Malacova, E., & Roughead, E. E. (2014). Early discontinuation of endocrine therapy for breast cancer: Who is at risk in clinical practice? SpringerPlus, 3, 282.
27. Knauper, B., & Turner, P.A. (2003). Measuring health: Improving the validity of health assessments. Quality of Life Research, 12(Suppl1), 81-89.
28. Lewinsohn, P. M., Seeley, J. R., Roberts, R. E., & Allen, N. B. (1997). Center for epidemiological studies-depression scale (ces-d) as a screening instrument for depression among community-residing older adults. Psychology and Aging, 12, 277-287.
29. Litton, J. K., Arun, B. K., Brown, P. H., & Hortobagyi, G. N. (2012). Aromatase inhibitors and breast cancer prevention. Expert Opinion on Pharmacotherapy, 13(3), 325-331.
30. Massie, M. J. (2004). Prevalence of depression in cancer patients. Journal of the National Cancer Institute Monographs, 32, 57-71.
31. Miilunpalo, S., Vuori, I., Oja, P., Pasanen, M., & Urponen, H. (1997). Self-rated health status as a health measure: The predictive value of self-rated health status on the use of physicians services and on mortality in the working-age population. Journal of Clinical Epidemiology, 50(5), 517-528.
32. Morales, L., Neven, P., Timmerman, D., Christiaens, R., Vergote, I., Van Limbergen, E., ⋯ Paridaens, R. (2004). Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anti-Cancer Drugs, 15(8), 753-760.
33. Ohsumi, S., Shimozuma, K., Ohashi, Y., Shinji, M., Hozumi, Y., Mukai, H., ⋯ Aihara, T. (2011). Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1-4 years: n-sas bc 03. Breast Cancer Research and Treatment, 127, 143-152.
34. Olufade, T., Gallicchio, L., MacDonald, R., & Helzlsouer, K. J. (2015). Musculoskeletal pain and health-related quality of life among breast cancer patients treated with aromatase inhibitors. Supportive Care in Cancer, 23, 447-455.
35. Onitilo, A. A., Nietert, P. J., & Egede, L. E. (2006). Effects of depression on all-cause mortality in adults with cancer and differential effects by cancer site. General Hospital Psychiatry, 28, 396-402.
36. Polsky, D., Doshi, J. A., Marcus, S., Oslin, D., Rothbard, A., ⋯ Thompson, C. L. (2005). Long-term risk for depressive symptoms after a medical diagnosis. Archives of Internal Medicine, 165, 1260-1266.
37. Radloff, R. L. (1977). The ces-d scale: A self-report depression scale for research in the general population. Applied Psychological Measurement, 1(3), 385-401.
38. Reyes-Gibby, D. D., Anderson, K. O., Morrow, P. K., Shete, S., & Hassan, S. (2012). Depressive symptoms and health-related quality of life in breast cancer survivors. Journal of Women's Health, 21(3), 311-318.
39. Roth, E. B., Jeffe, D. B., Margenthaler, J. A., & Aft, R. L. (2009). Method of breast cancer presentation and depressed mood 1 year after diagnosis in women with locally advanced disease. Annals of Surgical Oncology, 16, 1637-1641.
40. Rugo, H. S. (2008). The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: Evolving management options focusing on aromatase inhibitors. Annals of Oncology, 19, 16-27.
41. Schreiber, K., Kehlet, H., Belfer, I., & Edwards, R. (2014). Predicting, preventing and managing persistent pain after breast cancer surgery: The importance of psychosocial factors. Pain Management, 4(6), 445-459.
42. Schilder, C. M., Eggens, P. C., Seynaeve, C., Linn, S. C., Boogerd, W., Gundy, C. M., ⋯ Schagen, S. B. (2009). Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after ac-chemotherapy: Cross-sectional findings from the neuropsychological team-side study. Acta Oncologica, 48, 76-85.
43. Sehdev, S., Martin, G., Sideris, L., Lam, W., & Brisson, S. (2009). Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer. Current Oncology, 16(Suppl2), S14-S22.
44. Takei, H., Ohsumi, S., Shimozuma, K., Takehara, M., Suemasu, K., Ohashi, Y., & Hozumi, Y. (2012). Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National surgical adjuvant study of breast cancer 04 (n-sas bc04). Breast Cancer Research and Treatment, 133, 227-236.
45. Wasan, K. M., Goss, P. E., Pritchard, P. H., Sheperd, L., Palmer, M. J., Liu, S., ⋯ Perez, E. A. (2005). The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (ncic ctg ma.17l). Annals of Oncology, 16, 707-715.